German Breast Group - Clinical Reasearch under better Conditions

"Healing through innovation, competence and partnership" has been the vision of the GBG Research Institute since its foundation in April 2003.

These cornerstones of our work allow us professional handling of clinical trials with the highest quality standards, maximum scientific independence and professional neutrality.

Clinical trials exploring new methods of treatment nowadays represent a central element of medical research. In order to achieve a balanced level of knowledge, we consider it to be indispensable that clinical trials are conducted not only by manufacturers of pharmaceutics and medicinal products, but also by academic groups.

Significant to the success of our clinical trials is our collaboration and partnership with investigators and trial staff and their trial participants, as well as the manufacturers of pharmaceutics. We have at our disposal a network of approximately 500 study sites and 1000 clinical investigators. Furthermore, we cooperate with a multitude of both national and international study groups as well as most of the pharmaceutical companies which develop drugs for the treatment of breast cancer.

 

GBG Beiträge beim San Antonio Breast Cancer Symposium 2014

This text is only available in German.


Auch in diesem Jahr ist die GBG sehr erfolgreich beim San Antonio Kongress vertreten. Alle von uns eingereichten Abstracts sind akzeptiert worden. Im Folgenden finden Sie eine Übersicht.

 

9. December 2014

Educational Session: Invited Speaker SIBYLLE LOIBL: Neoadjuvant therapy in HER2 positive breast cancer, latest developments and biomarkers and how it serves as a discovery platform EDUCATIONAL SESSION: HER2 Positive Breast Cancer: Insights from the Lab and Clinic

Time: 2:00 pm – 3:30 pm

Room: Ballroom B

Presentation: 2:25 pm – 2:50 pm

 

10. December 2014

General Session 2: Oral presentation MICHAEL UNTCH: S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 POSTER DISCUSSION 2: Randomized Trials - Successes and Failure

Time: 3:15 pm – 5:00 pm

Room: Hall D

Presentation: 4:45 pm – 5:00 pm

 

11. December 2014

Slide presentation: GUNTER VON MINCKWITZ: S3-04 The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer GENERAL SESSION 3

Time: 9:30 am - 12:00 pm

Room: Exhibit Hall D

Presentation: 10:15 am – 10:30 am

 

11. December 2014

Poster presentation: SIBYLLE LOIBL: P3-06-12 Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial POSTER SESSION 3: Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors

Time: 5:00 pm – 7:00 pm

Room: Hall A-B

 

11. December 2014

Poster presentation: BERND GERBER: P3-11-01. Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44) POSTER SESSION 3: Treatment: Neoadjuvant Chemotherapy

Time: 5:00 pm – 7:00 pm

Room: Hall A-B

 

12. December 2014

Poster discussion: SIBYLLE LOIBL: PD5-7 PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer POSTER DISCUSSION 5: Targeting the PI3K Pathway

Time: 5:00 pm – 7:00 pm

Room: Ballroom A

   

GAIN-2 - The trial for high-risk breast cancer

The  typical GAIN-2-patient:

  • HER2-positive or triple-negative tumor irrespective of nodal status or
  • Luminal B-tumor (ER and/or PgR-positive, HER2-negative, Ki-67 > 20%) with positive lymph nodes or
  • at least 4 affected lymph nodes.

Trial design:

More about this trial is found here.

   

Trials presented at ASCO 2014

Panel presentations

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC) – Results from GeparSixto trial

Presentation

Posters


Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP). Loibl et al

GAIN (German Adjuvant Intergroup Node Positive) study: A phase III trial to compare idd-ETC vs. EC-TX in patients with node-positive primary breast cancer – final efficacy analysis. Möbus et al

Prognostic score for Luminal A-like breast cancer patients: the STage-Age-Receptors (STAR) score. Fontanella et al

 

   

2nd Breast Cancer in Young Women Conference (BCY2)

2nd Breast Cancer in Young Women Conference (BCY2)

Read more: 2nd Breast Cancer in Young Women Conference (BCY2)

   

2. Interdisziplinäre Frauenkonferenz der DGHO

This text is only available in German.


14 November 2014 - Heidelberg, Marriott Hotel
10:00-17:00 Uhr
Anmeldung per Fax an 030 / 27 87 60 89 - 18
oder melden Sie sich hier online unter dem Menüpunkt "Frauenkonferenz 2014" an.
 

 

Organisation:

DGHO Service GmbH

Alexanderplatz 1

10178 Berlin

Tel: 030-27 87 60 89 - 37

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

www.dgho-service.de

 

Veranstalter:

DGHO e.V.

Alexanderplatz 1

10178 Berlin

 

   

more news

more News...